‣ For inclusion in the study, patients should fulfill the following criteria:

• Age ≥18 at the time of signing the ICF.

• Provision of tumor sample to assess the PD-L1 expression.

• Measurable disease according to RECIST 1.1.

• ECOG performance status of 0 or 1.

• Life expectancy ≥ 12 weeks.

• Adequate organ and bone marrow function.

• Body weight \> 35 kg.

• Capable of giving signed informed consent.

• For sub-study 1, participants with R/M cervical cancer with squamous cell, adenocarcinoma or adenosquamous histology, that: have experienced disease progression during or after treatment with standard systematic therapy per local guideline; have received at least 1 line but no more than 2 lines of prior systemic treatment regimens for R/M cervical cancer.

⁃ For sub-study 2, for participants with OPC must have documented HPV status.

⁃ For sub-study 2, participants with R/M HNSCC, that: (a) Are histologically or cytologically documented R/M HNSCC of the OP, OC, HP, and LX that is considered incurable by local therapies; (b) Participants that have not been treated in R/M setting must have: (i) a documented PD-L1 positive result, (ii) with no prior systemic anti-cancer therapy for R/M HNSCC; (c) Platinum refractory participants must have relapsed from or are refractory to the first line of prior platinum-containing regimen.

⁃ For sub-study 3, participants with R/M HNSCC, that: (a) Are histologically or cytologically documented R/M HNSCC of the OP, OC, HP, and LX that is considered incurable by local therapies; (b) Participants that have not been treated in R/M setting